Drugs / BW-50218
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07577479 | May 2026 → Jun 2027 expected | — | Shanghai Argo Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07401472 | Mar 2026 → Jun 2027 expected | — | Shanghai Argo Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-28 | Shanghai Argo Biopharmaceutical Co., Ltd. | Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218 argobiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-50218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07401472 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered BW-50218” NCT07401472 ↗ |